Zealand Pharma’s Head of Research and Development Adam Steensberg has sold shares worth USD 655,000 (DKK 4.1m), the company reports in a statement.
On Thursday, the head of research and development sold 20,000 shares valued at USD 33 (DKK 207) per share.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.